PT043 Diagnostic and prognostic value of the B-type natriuretic peptide in elderly patients, in south Brazil, with suspected heart failure in the emergency room

Global Heart ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e173-e174
Author(s):  
Eduardo Pitthan ◽  
Juarez N. Barbisan ◽  
Patrícia S. Sant'Anna ◽  
Bruna H. Suzigan ◽  
Isabella D.A. Dossin ◽  
...  
Keyword(s):  
Heart Failure ◽  
Elderly Patients ◽  
Emergency Room ◽  
Natriuretic Peptide ◽  
Prognostic Value ◽  
Diagnostic And Prognostic Value ◽  
South Brazil

scholarly journals Amino Acid-Based Metabolic Panel Provides Robust Prognostic Value Additive to B-Natriuretic Peptide and Traditional Risk Factors in Heart Failure

2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Chao-Hung Wang ◽  
Mei-Ling Cheng ◽  
Min-Hui Liu
Keyword(s):  
Risk Factors ◽  
Heart Failure ◽  
Amino Acid ◽  
Natriuretic Peptide ◽  
Prognostic Value ◽  
Validation Cohort ◽  
Left Ventricular Ejection ◽  
Composite Events ◽  
Traditional Risk Factors ◽  
Diagnostic And Prognostic Value

Metabolic disturbances represent functional perturbation in peripheral tissues and predict outcomes in patients with heart failure (HF). This study developed an amino acid-based metabolic panel and sought to see whether this panel could add diagnostic and prognostic value to currently used B-type natriuretic peptide (BNP) measurements. Mass spectrometry and ultra-performance liquid chromatography were performed on 1288 participants, including 129 normal controls and 712 patients at HF stages A to D in the initial cohort and 447 stage C patients in the validation cohort. Patients were followed up for composite events (death/HF-related rehospitalization). Histidine, ornithine, and phenylalanine were 3 metabolites found strongly significant to identify patients at stage C and were adopted to develop the HOP panel. Compared to BNP, HOP had better value in discriminating the patients at different stages, especially in elderly patients and those with atrial fibrillation, high body mass index, or kidney dysfunction. HOP was correlated with the distance of 6 min walking distance better than BNP. For prognosis, HOP predicted composite events in patients at stages C and D, independent of log (BNP), age, sex, left ventricular ejection fraction, New York Heart Association functional class, HF stage, diabetes mellitus, chronic kidney disease, hypertension, hemoglobin, and albumin. Higher BNP (≥750 pg/mL) along with higher HOP (≥14) robustly predicted lower event-free survival compared to all others [hazard ratio=3.15 (2.23–4.46), p<0.001]. The prognostic value of HOP was confirmed in the validation cohort. In conclusion, aiming for clinical applications, this study proved that the HOP panel provides diagnostic and prognostic value additive to BNP and traditional risk factors.

Atrial natriuretic peptides in heart failure: pathophysiological significance, diagnostic and prognostic value

2011 ◽  
Vol 89 (8) ◽  
pp. 587-591 ◽  
Author(s):  
Nina Ghosh ◽  
Haissam Haddad
Keyword(s):  
Heart Failure ◽  
Natriuretic Peptide ◽  
Natriuretic Peptides ◽  
Prognostic Value ◽  
Diagnostic Value ◽  
Grey Zone ◽  
Long Term Effects ◽  
Diagnosis And Prognosis ◽  
Diagnostic And Prognostic Value ◽  
Atrial Natriuretic

Neurohormonal activation in patients with heart failure is dominated by the deleterious long-term effects of activation of the sympathetic nervous system and the renin–angiotensin–aldosterone system. The natriuretic peptides, including brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP), are also upregulated in heart failure, and partially counteract these deleterious effects by promoting vasodilation, natriuresis, and diuresis. Although BNP has been established as an important biomarker in the diagnosis and prognosis of heart failure, growing evidence suggests that measurement of plasma ANP, specifically its metabolite mid-regional pro-ANP, has similar diagnostic and prognostic value. Furthermore, its measurement may provide incremental diagnostic value when BNP levels fall into “grey zone” levels and may be a more potent prognostic marker of mortality.

Prognostic value of N-terminal pro-B-type natriuretic peptide, cytokines and sCD40L in patients with acute heart failure

2006 ◽  
Vol 40 (6) ◽  
pp. 953
Author(s):  
Radek Pudil ◽  
Milos Tichy ◽  
Ctirad Andrys ◽  
Marcela Drahosova ◽  
Vaclav Blaha ◽  
...  
Keyword(s):  
Heart Failure ◽  
Acute Heart Failure ◽  
Natriuretic Peptide ◽  
Prognostic Value

Diagnostic and Prognostic Value of Plasma Levels of Cardiac Myosin Binding Protein-C as a Novel Biomarker in Heart Failure

2016 ◽  
Vol 38 (2) ◽  
pp. 418-424 ◽  
Author(s):  
Doaa El Amrousy ◽  
Hossam Hodeib ◽  
Ghada Suliman ◽  
Nahed Hablas ◽  
Eman Ramadan Salama ◽  
...  
Keyword(s):  
Heart Failure ◽  
Plasma Levels ◽  
Protein C ◽  
Prognostic Value ◽  
Binding Protein ◽  
Cardiac Myosin ◽  
Myosin Binding Protein ◽  
Myosin Binding Protein C ◽  
Myosin Binding ◽  
Diagnostic And Prognostic Value

scholarly journals Extrém magas B típusú natriureticus prohormon prognosztikai szerepe a szívelégtelenség miatt kezelt betegek kórházi halálozására

2017 ◽  
Vol 158 (20) ◽  
pp. 779-782
Author(s):  
Béla Bózsik ◽  
Erzsébet Nagy ◽  
Miklós Somlói ◽  
János Tomcsányi
Keyword(s):  
Heart Failure ◽  
Hospital Mortality ◽  
Hospital Stay ◽  
Natriuretic Peptide ◽  
Natriuretic Peptides ◽  
Prognostic Value ◽  
Response To Therapy ◽  
Cardiology Department ◽  
The Difference ◽  
One Year

Abstract: Introduction: Patients hospitalized for heart failure have a very high in-hospital as well as one-year mortality. Natriuretic peptides play both a diagnostic and a prognostic role in this disease. Changes of natriuretic peptide levels in response to therapy are a well-known prognostic marker. Regarding in-hospital mortality, however, little is known about the prognostic value of extremely high levels of natriuretic peptides measured on admission. Aim: To decide whether extremely high levels of B-type natriuretic peptide have a prognostic value with regard to in-hospital mortality. Method: NT-proBNP levels on admission and in-hospital mortality were extracted retrospectively from the data of patients treated with heart failure in the cardiology department of the Hospital of St. John of God in Budapest. We separately analyzed the data of patients hospitalized for heart failure in 2015 with extremely high initial NT-proBNP levels. The cut-off value in this regard was 10 000 ng/l. We also analyzed the comorbidities of these patients. Results: The median NT-proBNP level of those patients who survived beyond the index hospital stay in the last 10 years was 4842 ng/l, whereas the median NT-proBNP level of those 182 patients who died during their hospital stay was 10 688 ng/l (p<0.001). In the year 2015, we treated 118 patients with an NT-proBNP level above 10 000 ng/l. Thirteen of these patients died, which means that their in-hospital mortality exceeded 10%. In comparison, the in-hospital mortality of all heart failure patients was 5.8%. The difference of median NT-proBNP levels of surviving versus deceased patients in this group with extremely high NT-proBNP levels was no longer significant (17 080 ng/l vs. 19 152 ng/l). Conclusions: Patients with an NT-proBNP level of >10 000 ng/l on admission have a significantly higher in-hospital mortality. The difference of NT-proBNP levels of surviving versus deceased patients in the group with admission NT-proBNP levels >10 000 ng/l is no longer significant. We could not identify any etiological factors that would explain these extremely high NT-proBNP levels or the excess in-hospital mortality. Orv Hetil. 2017; 158(20): 779–782.

Sign in / Sign up

Export Citation Format

Share Document